Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
17 hedge funds and large institutions have $137K invested in Vyant Bio, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
38% less capital invested
Capital invested by funds: $222K → $137K (-$85.3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$17.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.97K |
| 4 |
VF
Virtu Financial
New York
|
+$758 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$404 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$78.3K |
| 2 |
HF
HRT Financial
New York
|
-$11K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.88K |
| 4 |
Renaissance Technologies
New York
|
-$398 |
| 5 |
Morgan Stanley
New York
|
-$258 |
VYNT Hedge Fund Activity: Q1 2023 in Review
17 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q1 2023, worth a combined $137K — down 38% from $222K a quarter earlier.
Fund positioning in VYNT was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $17.8K. The largest seller was Vanguard Group, cutting an estimated $78.3K.
- 17 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $137K of Vyant Bio, Inc. Common Stock stock for Q1 2023, down 38% quarter-over-quarter.
- 3 funds opened new Vyant Bio, Inc. Common Stock positions in Q1 2023 and 3 closed out, a net change of 0 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q1 2023 was Millennium Management, an estimated $17.8K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q1 2023 was Vanguard Group, an estimated $78.3K sold.
Based on aggregated 13F filings for Q1 2023.